{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:41:01Z","timestamp":1792622461042,"version":"4.5.0"},"reference-count":109,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>Gouty arthritis is a type of inflammatory arthritis that is mediated by the deposition of monosodium urate crystals and is an important burden on healthcare worldwide. The aim of this comprehensive review is to discuss the most recent advances regarding the mechanisms of treatment for gout, from classic pharmacological interventions to emerging therapeutic strategies. The chapter dissects the pathophysiology of gout through hyperuricemia, crystal deposition, and inflammatory responses to form a basis for the discussion of current treatment approaches; pharmacological interventions are described-side by side with lifestyle modifications-including NSAIDs, colchicine, and xanthine oxidase inhibitors. Newer approaches to management are discussed, including the use of biologics targeting IL-1\u03b2, newer agents in development, and personalized medicine. It also outlines the future directions in gout research, focusing on the development of novel imaging techniques, biomarkers for treatment response, and targeting novel pathways. This review serves as an overall guide for clinicians and researchers and all other stakeholders interested in further advancing the specialty of gouty arthritis.<\/jats:p>","DOI":"10.33549\/physiolres.935631","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T13:52:17Z","timestamp":1764597137000},"page":"693","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Understanding the Mechanisms of Treatment for Gouty Arthritis: A Comprehensive Review"],"prefix":"10.33549","author":[{"given":"S","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Galozzi P, Bindoli S, Doria A, Oliviero F, Sfriso P. Autoinflammatory features in gouty arthritis. J Clin Med 2021;10:1880. https:\/\/doi.org\/10.3390\/jcm10091880 DOI: 10.3390\/jcm10091880","DOI":"10.3390\/jcm10091880"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Keller SF, Mandell BF. Management and cure of gouty arthritis. Med Clin North Am 2021;105:297-310. https:\/\/doi.org\/10.1016\/j.mcna.2020.09.013 DOI: 10.1016\/j.mcna.2020.09.013","DOI":"10.1016\/j.mcna.2020.09.013"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 2020;16:380-390. https:\/\/doi.org\/10.1038\/s41584-020-0441-1 DOI: 10.1038\/s41584-020-0441-1","DOI":"10.1038\/s41584-020-0441-1"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Asghari KM, Zahmatyar M, Seyedi F, Motamedi A, Zolfi M, Alamdary SJ, Fazlollahi A, Shamekh A, Mousavi SE, Nejadghaderi SA. Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review. BMC Musculoskelet Disord 2024;25:1047. https:\/\/doi.org\/10.1186\/s12891-024-08180-9 DOI: 10.1186\/s12891-024-08180-9","DOI":"10.1186\/s12891-024-08180-9"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Patil T, Soni A, Acharya S. A brief review on in vivo models for gouty arthritis. Metabol Open 2021;11:100100. https:\/\/doi.org\/10.1016\/j.metop.2021.100100 DOI: 10.1016\/j.metop.2021.100100","DOI":"10.1016\/j.metop.2021.100100"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Wilson L, Saseen JJ. Gouty arthritis: a review of acute management and prevention. Pharmacotherapy 2016;36:906-922. https:\/\/doi.org\/10.1002\/phar.1788 DOI: 10.1002\/phar.1788","DOI":"10.1002\/phar.1788"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, Pang Y, Zhang C, Zhong Z, Gao J. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther 2024;9:212. https:\/\/doi.org\/10.1038\/s41392-024-01916-y DOI: 10.1038\/s41392-024-01916-y","DOI":"10.1038\/s41392-024-01916-y"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. AlJadir S. Case report and disease review: Tophaceous gouty arthropathy. Endocrinol Metab Int J 2022;9:72-80. https:\/\/doi.org\/10.15406\/emij.2022.10.00312 DOI: 10.15406\/emij.2022.10.00312","DOI":"10.15406\/emij.2022.10.00312"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gout and diet: a comprehensive review of mechanisms and management. Nutrients 2022;14:3525. https:\/\/doi.org\/10.3390\/nu14173525 DOI: 10.3390\/nu14173525","DOI":"10.3390\/nu14173525"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, Stamp LK. Gout. Nat Rev Dis Primers 2019;5:69. https:\/\/doi.org\/10.1038\/s41572-019-0115-y DOI: 10.1038\/s41572-019-0115-y","DOI":"10.1038\/s41572-019-0115-y"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Nian Y-L, You C-G. Susceptibility genes of hyperuricemia and gout. Hereditas 2022;159:30. https:\/\/doi.org\/10.1186\/s41065-022-00243-y DOI: 10.1186\/s41065-022-00243-y","DOI":"10.1186\/s41065-022-00243-y"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T, Yamanashi Y, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 2012;3:764. https:\/\/doi.org\/10.1038\/ncomms1756 DOI: 10.1038\/ncomms1756","DOI":"10.1038\/ncomms1756"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Chen C, Wang J, Liang Z, Li M, Fu D, Zhang L, Yang X, Guo Y, Ge D, Liu Y. Monosodium urate crystals with controlled shape and aspect ratio for elucidating the pathological progress of acute gout. Biomater Adv 2022;139:213005. https:\/\/doi.org\/10.1016\/j.bioadv.2022.213005 DOI: 10.1016\/j.bioadv.2022.213005","DOI":"10.1016\/j.bioadv.2022.213005"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Galozzi P, Bindoli S, Luisetto R, Sfriso P, Ramonda R, Scanu A, Oliviero F. Regulation of crystal induced inflammation: current understandings and clinical implications. Expert Rev Clin Immunol 2021;17:773-787. https:\/\/doi.org\/10.1080\/1744666X.2021.1937129 DOI: 10.1080\/1744666X.2021.1937129","DOI":"10.1080\/1744666X.2021.1937129"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Cha Y, Lee J, Choy W, Lee JS, Lee HH, Chae D-S. Pathophysiology and treatment of gout arthritis; including gout arthritis of hip joint: a literature review. Hip Pelvis 2024;36:1. https:\/\/doi.org\/10.5371\/hp.2024.36.1.1 DOI: 10.5371\/hp.2024.36.1.1","DOI":"10.5371\/hp.2024.36.1.1"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Laurent MR. Bone and joint disorders. In: Geriatric Medicine: A Person Centered Evidence Based Approach. Wasserman MR, Bakerjian D, Linnebur S, Brangman S, Cesari M, Rosen S (eds), Springer Nature, 2024, pp 721-760. https:\/\/doi.org\/10.1007\/978-3-030-74720-6_61 DOI: 10.1007\/978-3-030-74720-6_61","DOI":"10.1007\/978-3-030-74720-6_61"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. Vandendriessche S, Cambier S, Proost P, Marques PE. Complement receptors and their role in leukocyte recruitment and phagocytosis. Front Cell Dev Biol 2021;9:624025. https:\/\/doi.org\/10.3389\/fcell.2021.624025 DOI: 10.3389\/fcell.2021.624025","DOI":"10.3389\/fcell.2021.624025"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Silva LB, dos Santos Neto AP, Maia SMAS, dos Santos Guimar\u00e3es C, Quidute IL, Carvalho AdAT, Severino A, et al. The role of TNF-\u03b1 as a proinflammatory cytokine in pathological processes. Open Dent J 2019;13:332-338. https:\/\/doi.org\/10.2174\/1874210601913010332 DOI: 10.2174\/1874210601913010332","DOI":"10.2174\/1874210601913010332"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Kaur H, Ghorai SM. Role of cytokines as immunomodulators. In: Immunomodulators and Human Health. Kesharwani RK, Keservani RK, Sharma AK (eds), Springer Nature, 2022, pp 371-414. https:\/\/doi.org\/10.1007\/978-981-16-6379-6_13 DOI: 10.1007\/978-981-16-6379-6_13","DOI":"10.1007\/978-981-16-6379-6_13"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20. Proudman C, Lester SE, Gonzalez-Chica DA, Gill TK, Dalbeth N, Hill CL. Gout, flares, and allopurinol use: a population-based study. Arthritis Res Ther 2019;21:1-8. https:\/\/doi.org\/10.1186\/s13075-019-1918-7 DOI: 10.1186\/s13075-019-1918-7","DOI":"10.1186\/s13075-019-1918-7"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Ekpenyong CE, Daniel N. Roles of diets and dietary factors in the pathogenesis, management and prevention of abnormal serum uric acid levels. PharmaNutrition 2015;3:29-45. https:\/\/doi.org\/10.1016\/j.phanu.2014.12.001 DOI: 10.1016\/j.phanu.2014.12.001","DOI":"10.1016\/j.phanu.2014.12.001"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Spragg JC, Michael TJ, Aslani P, Coleshill MJ, Chan JS, Day RO, Stocker SL. Optimizing adherence to allopurinol for gout: patients' perspectives. Br J Clin Pharmacol 2023;89:1978-1991. https:\/\/doi.org\/10.1111\/bcp.15657 DOI: 10.1111\/bcp.15657","DOI":"10.1111\/bcp.15657"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23. Soskind R, Abazia DT, Bridgeman MB. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares. Expert Opin Pharmacother 2017;18:1115-1125. https:\/\/doi.org\/10.1080\/14656566.2017.1349099 DOI: 10.1080\/14656566.2017.1349099","DOI":"10.1080\/14656566.2017.1349099"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24. Atkinson TJ, Fudin J. Nonsteroidal antiinflammatory drugs for acute and chronic pain. Phys Med Rehabil Clin N Am 2020;31:219-231. https:\/\/doi.org\/10.1016\/j.pmr.2020.01.002 DOI: 10.1016\/j.pmr.2020.01.002","DOI":"10.1016\/j.pmr.2020.01.002"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25. Gracheva IA, Shchegravina ES, Schmalz H-G, Beletskaya IP, Fedorov AY. Colchicine alkaloids and synthetic analogues: current progress and perspectives. J Med Chem 2020;63:10618-10651. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00222 DOI: 10.1021\/acs.jmedchem.0c00222","DOI":"10.1021\/acs.jmedchem.0c00222"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26. Stone S, Malanga GA, Capella T. Corticosteroids: review of the history, the effectiveness, and adverse effects in the treatment of joint pain. Pain Physician 2021;24(S1):S233-S246. https:\/\/doi.org\/10.36076\/ppj.2021.24.S233-S246 DOI: 10.36076\/ppj.2021.24.S233-S246","DOI":"10.36076\/ppj.2021.24.S233-S246"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27. Alghamdi AA, Althumali JS, Almalki MMM, Almasoudi AS, Almuntashiri AH, Almuntashiri AH, Mohammed AI, et al. An overview on the role of xanthine oxidase inhibitors in gout management. Arch Pharm Pract 2021;12:94-99. https:\/\/doi.org\/10.51847\/RkCPaycprc DOI: 10.51847\/RkCPaycprc","DOI":"10.51847\/RkCPaycprc"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28. Jenkins C, Hwang JH, Kopp JB, Winkler CA, Cho SK. Review of urate-lowering therapeutics: From the past to the future. Front Pharmacol 2022;13:925219. https:\/\/doi.org\/10.3389\/fphar.2022.925219 DOI: 10.3389\/fphar.2022.925219","DOI":"10.3389\/fphar.2022.925219"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29. Nielsen SM, Zobbe K, Kristensen LE, Christensen R. Nutritional recommendations for gout: An update from clinical epidemiology. Autoimmun Rev 2018;17:1090-1096. https:\/\/doi.org\/10.1016\/j.autrev.2018.05.008 DOI: 10.1016\/j.autrev.2018.05.008","DOI":"10.1016\/j.autrev.2018.05.008"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30. Rai SK, Fung TT, Lu N, Keller SF, Curhan GC, Choi HK. The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study. BMJ 2017;357:j1794. https:\/\/doi.org\/10.1136\/bmj.j1794 DOI: 10.1136\/bmj.j1794","DOI":"10.1136\/bmj.j1794"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31. Yokose C, McCormick N, Lu N, Joshi AD, Curhan G, Choi HK. Adherence to 2020 to 2025 Dietary Guidelines for Americans and the risk of new-onset female gout. JAMA Intern Med 2022;182:254-264. https:\/\/doi.org\/10.1001\/jamainternmed.2021.7419 DOI: 10.1001\/jamainternmed.2021.7419","DOI":"10.1001\/jamainternmed.2021.7419"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie\/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000;59:539-543. https:\/\/doi.org\/10.1136\/ard.59.7.539 DOI: 10.1136\/ard.59.7.539","DOI":"10.1136\/ard.59.7.539"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33. Kakutani-Hatayama M, Kadoya M, Okazaki H, Kurajoh M, Shoji T, Koyama H, Tsutsumi Z, et al. Nonpharmacological management of gout and hyperuricemia: hints for better lifestyle. Am J Lifestyle Med 2017;11:321-329. https:\/\/doi.org\/10.1177\/1559827615601973 DOI: 10.1177\/1559827615601973","DOI":"10.1177\/1559827615601973"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34. Ma W, Ye G, Liu Y, Sun W, Huang X, Hu L, Chen L, Huang B, Li H. Impact of alcohol consumption on hyperuricemia and gout: a systematic review and meta-analysis. Front Nutr 2025;12:1588980. https:\/\/doi.org\/10.3389\/fnut.2025.1588980 DOI: 10.3389\/fnut.2025.1588980","DOI":"10.3389\/fnut.2025.1588980"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35. Saag KG, Khanna PP, Keenan RT, Ohlman S, Osterling Koskinen L, Sparve E, \u00c5kerblad AC, Wik\u00e9n M, So A, Pillinger MH. A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. Arthritis Rheumatol 2021;73:1533-1542. https:\/\/doi.org\/10.1002\/art.41699 DOI: 10.1002\/art.41699","DOI":"10.1002\/art.41699"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36. Jena M, Tripathy A, Mishra A, Maiti R. Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis. Inflammopharmacology 2021;29:35-47. https:\/\/doi.org\/10.1007\/s10787-020-00753-z DOI: 10.1007\/s10787-020-00753-z","DOI":"10.1007\/s10787-020-00753-z"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37. Maher D, Reeve E, Hopkins A, Tan JM, Tantiongco M, Ailabouni N, Woodman R, et al. Comparative risk of gout flares when initiating or escalating various urate-lowering therapy: a systematic review with network meta-analysis. Arthritis Care Res (Hoboken) 2024;76:871-881. https:\/\/doi.org\/10.1002\/acr.25309 DOI: 10.1002\/acr.25309","DOI":"10.1002\/acr.25309"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38. Botson J, Obermeyer K, LaMoreaux B, Padnick-Silver L, Verma S, Weinblatt ME, Peterson J. Quality of life and clinical gout assessments during pegloticase with and without methotrexate co-therapy: MIRROR randomized controlled trial exploratory findings. Rheumatol Adv Pract 2024;8:rkae145. https:\/\/doi.org\/10.1093\/rap\/rkae145 DOI: 10.1093\/rap\/rkae145","DOI":"10.1093\/rap\/rkae145"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39. Yang S, Hu Q, Liu K, Xiao B, Zhang B, Su N. Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis. Front Pharmacol 2025;16:1551390. https:\/\/doi.org\/10.3389\/fphar.2025.1551390 DOI: 10.3389\/fphar.2025.1551390","DOI":"10.3389\/fphar.2025.1551390"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40. Tesfaye H, Wang KM, Zabotka LE, Wexler DJ, Schmedt N, Koeneman L, Seman L, et al. Empagliflozin and risk of incident gout: analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study. J Gen Intern Med 2024;39:1870-1879. https:\/\/doi.org\/10.1007\/s11606-024-08793-9 DOI: 10.1007\/s11606-024-08793-9","DOI":"10.1007\/s11606-024-08793-9"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41. Zhou J, Zhang Y, Cheng L. Meta-analysis of the effect of losartan relative to other angiotensin receptor antagonists on serum uric acid level. Trop J Pharm Res 2023;22:1999-2008. https:\/\/doi.org\/10.4314\/tjpr.v22i9.31 DOI: 10.4314\/tjpr.v22i9.31","DOI":"10.4314\/tjpr.v22i9.31"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42. Jiao X-F, Song K, Jiao X, Li H, Zeng L, Zou K, Zhang W, Wang H, Zhang L. Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: a real-world analysis using the FDA adverse event reporting system. Front Pharmacol 2023;13:1045561. https:\/\/doi.org\/10.3389\/fphar.2022.1045561 DOI: 10.3389\/fphar.2022.1045561","DOI":"10.3389\/fphar.2022.1045561"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43. Kaufmann D, Chaiyakunapruk N, Schlesinger N. Optimizing gout treatment: a comprehensive review of current and emerging uricosurics. Joint Bone Spine 2025;92:105826. https:\/\/doi.org\/10.1016\/j.jbspin.2024.105826 DOI: 10.1016\/j.jbspin.2024.105826","DOI":"10.1016\/j.jbspin.2024.105826"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44. Zairol Azwan FA, Teo YY, Mohd Tahir NA, Saffian SM, Makmor-Bakry M, Mohamed Said MS. A systematic review of single nucleotide polymorphisms affecting allopurinol pharmacokinetics and serum uric acid level. Pharmacogenomics 2024;25:479-494. https:\/\/doi.org\/10.1080\/14622416.2024.2403969 DOI: 10.1080\/14622416.2024.2403969","DOI":"10.1080\/14622416.2024.2403969"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45. Terkeltaub R, Lee J, Min J, Shin S, Saag KG. Serum urate-lowering efficacy and safety of tigulixostat in gout patients with hyperuricemia: a randomized, double-blind, placebo-controlled, dose-finding trial. Arthritis Rheumatol 2023;75:1275-1284. https:\/\/doi.org\/10.1002\/art.42447 DOI: 10.1002\/art.42447","DOI":"10.1002\/art.42447"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46. Saag KG, Dalbeth N, Hsu CY, Kuo CF, Nuki G, Perez-Ruiz F, White WB, et al. Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: design of the EURELIA 1 and EURELIA 2 studies. Contemp Clin Trials 2025;151:107843. https:\/\/doi.org\/10.1016\/j.cct.2025.107843 DOI: 10.1016\/j.cct.2025.107843","DOI":"10.1016\/j.cct.2025.107843"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47. Hsu TM, Chang HW, Chen AL, Wei JC. Comment on serum urate-lowering efficacy and safety of tigulixostat in gout patients with hyperuricemia: a randomized, double-blind, placebo-controlled, dose-finding trial. Int J Rheum Dis 2024;27:e15024. https:\/\/doi.org\/10.1111\/1756-185X.15024 DOI: 10.1111\/1756-185X.15024","DOI":"10.1111\/1756-185X.15024"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48. Liu N, Xu H, Sun Q, Yu X, Chen W, Wei H, Jiang J, Xu Y, Lu W. The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors. Oxid Med Cell Longev 2021;2021:1470380. https:\/\/doi.org\/10.1155\/2021\/1470380 DOI: 10.1155\/2021\/1470380","DOI":"10.1155\/2021\/1470380"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49. Stockert AL, Stechschulte M. Allopurinol to febuxostat: how far have we come? Clin Med Insights Ther 2010;2:CMT.S6286. https:\/\/doi.org\/10.4137\/CMT.S6286 DOI: 10.4137\/CMT.S6286","DOI":"10.4137\/CMT.S6286"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50. Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet J-L. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther 2016;18:1-10. https:\/\/doi.org\/10.1186\/s13075-016-1150-7 DOI: 10.1186\/s13075-016-1150-7","DOI":"10.1186\/s13075-016-1150-7"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51. Wolff ML, Cruz JL, Vanderman AJ, Brown JN. The effect of angiotensin II receptor blockers on hyperuricemia. Ther Adv Chronic Dis 2015;6:339-346. https:\/\/doi.org\/10.1177\/2040622315596119 DOI: 10.1177\/2040622315596119","DOI":"10.1177\/2040622315596119"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52. Kumar N, Husain S, Haque ZU, Aleem A, Rizwan F, Bhatti MI. The effects of beta blocker (metoprolol) & calcium channel blockers (amlodipine) on serum uric acid levels in the patients of hypertension. Pak J Med Health Sci 2022;16:597-599. https:\/\/doi.org\/10.53350\/pjmhs22165597 DOI: 10.53350\/pjmhs22165597","DOI":"10.53350\/pjmhs22165597"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53. Szekanecz Z, Szamosi S, Kov\u00e1cs GE, Kocsis E, Benk\u0151 S. The NLRP3 inflammasome-interleukin 1 pathway as a therapeutic target in gout. Arch Biochem Biophys 2019;670:82-93. https:\/\/doi.org\/10.1016\/j.abb.2019.01.031 DOI: 10.1016\/j.abb.2019.01.031","DOI":"10.1016\/j.abb.2019.01.031"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54. Schlesinger N. Anti-interleukin-1 therapy in the management of gout. Curr Rheumatol Rep 2014;16:1-6. https:\/\/doi.org\/10.1007\/s11926-013-0398-z DOI: 10.1007\/s11926-013-0398-z","DOI":"10.1007\/s11926-013-0398-z"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55. So A, De Meulemeester M, Pikhlak A, Y\u00fccel AE, Richard D, Murphy V, Arulmani U, Sallstig P, Schlesinger N. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62:3064-3076. https:\/\/doi.org\/10.1002\/art.27600 DOI: 10.1002\/art.27600","DOI":"10.1002\/art.27600"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56. Jeria-Navarro S, Gomez-Gomez A, Park HS, Calvo-Aranda E, Corominas H, Pou MA, Diaz-Torne C. Effectiveness and safety of anakinra in gouty arthritis: a case series and review of the literature. Front Med (Lausanne) 2022;9:1089993. https:\/\/doi.org\/10.3389\/fmed.2022.1089993 DOI: 10.3389\/fmed.2022.1089993","DOI":"10.3389\/fmed.2022.1089993"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57. James R, Paul BJ. New and emerging therapies in gout. Rheumatol Autoimmun 2023;3:70-77. https:\/\/doi.org\/10.1002\/rai2.12064 DOI: 10.1002\/rai2.12064","DOI":"10.1002\/rai2.12064"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58. Pascart T, Richette P. Investigational drugs for hyperuricemia, an update on recent developments. Expert Opin Investig Drugs 2018;27:437-444. https:\/\/doi.org\/10.1080\/13543784.2018.1471133 DOI: 10.1080\/13543784.2018.1471133","DOI":"10.1080\/13543784.2018.1471133"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59. Zeng L, Deng Y, He Q, Yang K, Li J, Xiang W, Liu H, Zhu X, Chen H. Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: a systematic review and meta-analysis of 34 randomized controlled trials. Front Immunol 2022;13:961325. https:\/\/doi.org\/10.3389\/fimmu.2022.961325 DOI: 10.3389\/fimmu.2022.961325","DOI":"10.3389\/fimmu.2022.961325"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60. Han Y, Yao M, Zhao H, Han X, Di H, Xie T, Wu J, Wang Y, Zhang Y, Zeng X. Exploration of the interrelationship between serum uric acid, gout, and cardiac, renal, and metabolic conditions in middle-aged and older people. J Am Heart Assoc 2025;14:e038723. https:\/\/doi.org\/10.1161\/JAHA.124.038723 DOI: 10.1161\/JAHA.124.038723","DOI":"10.1161\/JAHA.124.038723"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61. Nieradko-Iwanicka B. What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension? Reumatologia (Rheumatol) 2018;56:106-110. https:\/\/doi.org\/10.5114\/reum.2018.75522 DOI: 10.5114\/reum.2018.75522","DOI":"10.5114\/reum.2018.75522"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62. Banerjee M, Pal R, Mukhopadhyay S. Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis. Acta Diabetol 2022;59:783-791. https:\/\/doi.org\/10.1007\/s00592-022-01866-3 DOI: 10.1007\/s00592-022-01866-3","DOI":"10.1007\/s00592-022-01866-3"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63. Wu R, Cheng YJ, Zhu LL, Yu L, Zhao XK, Jia M, Wen CH, et al. Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies. Oncotarget 2016;7:81870-81879. https:\/\/doi.org\/10.18632\/oncotarget.13250 DOI: 10.18632\/oncotarget.13250","DOI":"10.18632\/oncotarget.13250"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64. Ferngprayoon P, Sukasem C, Palapinyo S, Taibanguay N, Puttilerpong C. The outcome of HLA-B*58:01 screening test before initiating allopurinol at a tertiary hospital. Thai J Pharm Sci 2024;48:1. https:\/\/doi.org\/10.56808\/3027-7922.2967 DOI: 10.56808\/3027-7922.2967","DOI":"10.56808\/3027-7922.2967"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"65. Terashima R, Medina AJP, Del Mundo HJF, Briones RSS, Aquino JAB, Quiminiano EM, Sin YM, et al. Prevalence of Human Leukocyte Antigen (HLA)-B*58:01 and allopurinol-induced adverse reactions in Filipino patients in Hawai'i: implications for genotyping. Int J Rheum Dis 2025;28:e70127. https:\/\/doi.org\/10.1111\/1756-185X.70127 DOI: 10.1111\/1756-185X.70127","DOI":"10.1111\/1756-185X.70127"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"66. Stitt R, Pinto B, June R. AB1615-HPR HLAB5801 testing for patients at high risk for allopurinol hypersensitivity syndrome: a quality improvement initiative. Ann Rheum Dis 2024;83:2182-2183. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.2403 DOI: 10.1136\/annrheumdis-2024-eular.2403","DOI":"10.1136\/annrheumdis-2024-eular.2403"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"67. Pavelcova K, Bohata J, Pavlikova M, Bubenikova E, Pavelka K, Stiburkova B. Evaluation of the influence of genetic variants of SLC2A9 (GLUT9) and SLC22A12 (URAT1) on the development of hyperuricemia and gout. J Clin Med 2020;9:2510. https:\/\/doi.org\/10.3390\/jcm9082510 DOI: 10.3390\/jcm9082510","DOI":"10.3390\/jcm9082510"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"68. Cleophas M, Joosten L, Stamp LK, Dalbeth N, Woodward OM, Merriman TR. ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches. Pharmacogenomics Pers Med 2017;10:129-142. https:\/\/doi.org\/10.2147\/PGPM.S105854 DOI: 10.2147\/PGPM.S105854","DOI":"10.2147\/PGPM.S105854"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"69. Alrajeh KY, Roman YM. Pharmacogenetic perspective for optimal gout management. Future Pharmacol 2022;2:135-152. https:\/\/doi.org\/10.3390\/futurepharmacol2020011 DOI: 10.3390\/futurepharmacol2020011","DOI":"10.3390\/futurepharmacol2020011"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"70. Pillinger MH, Mandell BF. Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum 2020;50(3S):S24-S30. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.04.010 DOI: 10.1016\/j.semarthrit.2020.04.010","DOI":"10.1016\/j.semarthrit.2020.04.010"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"71. Lin Z, Gupta JK, Maqbool M, Kumar K, Sharma A, Wahi N. The therapeutic management of chemical and herbal medications on uric acid levels and gout: modern and traditional wisdom. Pharmaceuticals (Basel) 2024;17:1507. https:\/\/doi.org\/10.3390\/ph17111507 DOI: 10.3390\/ph17111507","DOI":"10.3390\/ph17111507"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"72. Terkeltaub R. Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review. Drugs 2023;83:1501-1521. https:\/\/doi.org\/10.1007\/s40265-023-01944-y DOI: 10.1007\/s40265-023-01944-y","DOI":"10.1007\/s40265-023-01944-y"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"73. Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules 2020;25:1987. https:\/\/doi.org\/10.3390\/molecules25081987 DOI: 10.3390\/molecules25081987","DOI":"10.3390\/molecules25081987"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"74. Terkeltaub R, Dodd D. The Gut Microbiome in Hyperuricemia and Gout. Arthritis Rheumatol 2025;77:955-965. https:\/\/doi.org\/10.1002\/art.43118 DOI: 10.1002\/art.43118","DOI":"10.1002\/art.43118"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"75. Kiltz U, Smolen J, Bardin T, Solal AC, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis 2017;76:632-638. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209467 DOI: 10.1136\/annrheumdis-2016-209467","DOI":"10.1136\/annrheumdis-2016-209467"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"76. Uhlig T, Karoliussen LF, Sexton J, Borgen T, Haavardsholm EA, Kvien TK, Hammer HB. 12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target. RMD Open 2021;7:e001628. https:\/\/doi.org\/10.1136\/rmdopen-2021-001628 DOI: 10.1136\/rmdopen-2021-001628","DOI":"10.1136\/rmdopen-2021-001628"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"77. Solomon DH, Paudel M, Chitineni S, Fernandes A, Pham T, Billa S, Yokose C, et al. The design of a randomized controlled active-comparator strategy trial for gout: treat to target serum urate versus treat to avoid symptoms. ACR Open Rheumatol 2025;7:e70012. https:\/\/doi.org\/10.1002\/acr2.70012 DOI: 10.1002\/acr2.70012","DOI":"10.1002\/acr2.70012"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"78. Yang AY. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases. Int J Clin Pharmacol Ther 2020;58:21. https:\/\/doi.org\/10.5414\/CP203466 DOI: 10.5414\/CP203466","DOI":"10.5414\/CP203466"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"79. Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol 2014;20:427-432. https:\/\/doi.org\/10.1097\/RHU.0000000000000200 DOI: 10.1097\/RHU.0000000000000200","DOI":"10.1097\/RHU.0000000000000200"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"80. Cicero AF, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical effects of xanthine oxidase inhibitors in hyperuricemic patients. Med Princ Pract 2021;30:122-130. https:\/\/doi.org\/10.1159\/000512178 DOI: 10.1159\/000512178","DOI":"10.1159\/000512178"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"81. Chen SK, Liu J, Kim SC. Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study. BMJ Open 2020;10:e041167. https:\/\/doi.org\/10.1136\/bmjopen-2020-041167 DOI: 10.1136\/bmjopen-2020-041167","DOI":"10.1136\/bmjopen-2020-041167"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"82. Howren A, Tsao NW, Choi HK, Shojania K, Kydd A, Friesen R, Avina-Zubieta JA, De Vera MA. eHealth-supported decentralized multi-disciplinary care for gout involving rheumatology, pharmacy, and dietetics: proof-of-concept study. Clin Rheumatol 2020;39:1241-1249. https:\/\/doi.org\/10.1007\/s10067-019-04809-6 DOI: 10.1007\/s10067-019-04809-6","DOI":"10.1007\/s10067-019-04809-6"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"83. Tsiamalou P, Brotis AG, Vrekou E, Georgakopoulou VE, Papalexis P, Aravanatinou-Fatorou A, Tegousi M, Fotakopoulos G, Paterakis K. The nurse's role in managing gout in the modern era: a systematic review of the literature. Medicine (Baltimore) 2023;3:40. https:\/\/doi.org\/10.3892\/mi.2023.100 DOI: 10.3892\/mi.2023.100","DOI":"10.3892\/mi.2023.100"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"84. Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, Barclay C, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomized controlled trial. Lancet 2018;392:1403-1412. https:\/\/doi.org\/10.1016\/S0140-6736(18)32158-5 DOI: 10.1016\/S0140-6736(18)32158-5","DOI":"10.1016\/S0140-6736(18)32158-5"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"85. Yao TK, Lee RP, Wu WT, Chen IH, Yu TC, Yeh KT. Advances in Gouty Arthritis Management: Integration of Established Therapies, Emerging Treatments, and Lifestyle Interventions. Int J Mol Sci 2024;25:10853. https:\/\/doi.org\/10.3390\/ijms251910853 DOI: 10.3390\/ijms251910853","DOI":"10.3390\/ijms251910853"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"86. Mikuls TR, Cheetham TC, Levy GD, Rashid N, Kerimian A, Low KJ, Coburn BW, et al. Adherence and outcomes with urate-lowering therapy: a site-randomized trial. Am J Med 2019;132:354-361. https:\/\/doi.org\/10.1016\/j.amjmed.2018.11.011 DOI: 10.1016\/j.amjmed.2018.11.011","DOI":"10.1016\/j.amjmed.2018.11.011"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"87. Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ 2013;346:f3195. https:\/\/doi.org\/10.1007\/978-3-0348-0620-6_52-2 DOI: 10.1007\/978-3-0348-0620-6_52-2","DOI":"10.1007\/978-3-0348-0620-6_52-2"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"88. Kapugi M, Cunningham K. Corticosteroids. Orthop Nurs 2019;38:336-339. https:\/\/doi.org\/10.1097\/NOR.0000000000000595 DOI: 10.1097\/NOR.0000000000000595","DOI":"10.1097\/NOR.0000000000000595"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"89. Perez-Ruiz F, Desideri G. Improving adherence to gout therapy: an expert review. Ther Clin Risk Manag 2018;793-802. https:\/\/doi.org\/10.2147\/TCRM.S162956 DOI: 10.2147\/TCRM.S162956","DOI":"10.2147\/TCRM.S162956"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"90. Spragg JC, Michael TJ, Aslani P, Coleshill MJ, Chan JS, Day RO, Stocker SL. Optimizing adherence to allopurinol for gout: patients' perspectives. Br J Clin Pharmacol 2023;89:1978-1991. https:\/\/doi.org\/10.1111\/bcp.15657 DOI: 10.1111\/bcp.15657","DOI":"10.1111\/bcp.15657"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"91. Rai SK, Choi HK, Choi SH, Townsend AF, Shojania K, De Vera MA. Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies. Rheumatology (Oxford) 2018;57:1282-1292. https:\/\/doi.org\/10.1093\/rheumatology\/kex530 DOI: 10.1093\/rheumatology\/kex530","DOI":"10.1093\/rheumatology\/kex530"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"92. Michael TJ, Wright DF, Chan JS, Coleshill MJ, Aslani P, Hughes DA, Day RO, Stocker SL. Patient-led urate self-monitoring to improve clinical outcomes in people with gout: a feasibility study. ACR Open Rheumatol 2024;6:403-411. https:\/\/doi.org\/10.1002\/acr2.11666 DOI: 10.1002\/acr2.11666","DOI":"10.1002\/acr2.11666"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"93. Robinson PC. Gout-an update of aetiology, genetics, co-morbidities and management. Maturitas 2018;118:67-73. https:\/\/doi.org\/10.1016\/j.maturitas.2018.10.012 DOI: 10.1016\/j.maturitas.2018.10.012","DOI":"10.1016\/j.maturitas.2018.10.012"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"94. Guthridge JM, Wagner CA, James JA. The promise of precision medicine in rheumatology. Nat Med 2022;28:1363-1371. https:\/\/doi.org\/10.1038\/s41591-022-01880-6 DOI: 10.1038\/s41591-022-01880-6","DOI":"10.1038\/s41591-022-01880-6"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"95. Gali\u0107 I, Habijan M, Leventi\u0107 H, Romi\u0107 K. Machine learning empowering personalized medicine: a comprehensive review of medical image analysis methods. Electronics 2023;12:4411. https:\/\/doi.org\/10.3390\/electronics12214411 DOI: 10.3390\/electronics12214411","DOI":"10.3390\/electronics12214411"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"96. Ero\u011ful \u00d6, Ert\u00fcrk A, Do\u011fan M, Kurt K, Ka\u015f\u0131kc\u0131 M. Evaluation of macular and optic disc radial peripapillary vessel density using optical coherence tomography angiography in gout patients. Diagnostics (Basel) 2023;13:3651. https:\/\/doi.org\/10.3390\/diagnostics13243651 DOI: 10.3390\/diagnostics13243651","DOI":"10.3390\/diagnostics13243651"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"97. Xie J, He C, Su Y, Ding Y, Zhu X, Xu Y, Ding J, Zhou H, Wang H. Research progress on microRNA in gout. Front Pharmacol 2022;13:981799. https:\/\/doi.org\/10.3389\/fphar.2022.981799 DOI: 10.3389\/fphar.2022.981799","DOI":"10.3389\/fphar.2022.981799"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"98. Barshop BA, Nyhan WL. Purines and pyrimidines. In: Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease. Rosenberg RN, Pascual JM (eds), Academic Press, 2025, pp 897-916. https:\/\/doi.org\/10.1016\/B978-0-443-19041-4.00025-X DOI: 10.1016\/B978-0-443-19041-4.00025-X","DOI":"10.1016\/B978-0-443-19041-4.00025-X"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"99. Yang Q, Su L, Zhao L. Research progress of drugs for the treatment of gout. Int J Biol Life Sci 2023;4:40-42. https:\/\/doi.org\/10.54097\/ijbls.v4i3.11 DOI: 10.54097\/ijbls.v4i3.11","DOI":"10.54097\/ijbls.v4i3.11"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"100. Nag S, Mohanto S, Ahmed MG, Subramaniyan V. \"Smart\" stimuli-responsive biomaterials revolutionizing the theranostic landscape of inflammatory arthritis. Mater Today Chem 2024;39:102178. https:\/\/doi.org\/10.1016\/j.mtchem.2024.102178 DOI: 10.1016\/j.mtchem.2024.102178","DOI":"10.1016\/j.mtchem.2024.102178"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"101. Coppola C, Greco M, Munir A, Musar\u00f2 D, Quarta S, Massaro M, Lionetto MG, Maffia M. Osteoarthritis: insights into diagnosis, pathophysiology, therapeutic avenues, and the potential of natural extracts. Curr Issues Mol Biol 2024;46:4063-4105. https:\/\/doi.org\/10.3390\/cimb46050251 DOI: 10.3390\/cimb46050251","DOI":"10.3390\/cimb46050251"},{"key":"ref101","unstructured":"102. Bland JS. Therapeutic use of omega-3 fatty acids for immune disorders in search of the ideal omega-3 supplement. Integr Med (Encinitas) 2022;21:14-18."},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"103. Ja\u00e9n RI, S\u00e1nchez-Garc\u00eda S, Fern\u00e1ndez-Velasco M, Bosc\u00e1 L, Prieto P. Resolution-based therapies: the potential of lipoxins to treat human diseases. Front Immunol 2021;12:658840. https:\/\/doi.org\/10.3389\/fimmu.2021.658840 DOI: 10.3389\/fimmu.2021.658840","DOI":"10.3389\/fimmu.2021.658840"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"104. Memarzia A, Khazdair MR, Behrouz S, Gholamnezhad Z, Jafarnezhad M, Saadat S, Boskabady MH. Experimental and clinical reports on anti-inflammatory, antioxidant, and immunomodulatory effects of Curcuma longa and curcumin, an updated and comprehensive review. BioFactors 2021;47:311-350. https:\/\/doi.org\/10.1002\/biof.1716 DOI: 10.1002\/biof.1716","DOI":"10.1002\/biof.1716"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"105. Imperador CHL, Scarim CB, Bosquesi PL, Lopes JR, Cardinalli Neto A, Giarolla J, Ferreira EI, Dos Santos JL, Chin CM. Resveratrol and curcumin for Chagas disease treatment-a systematic review. Pharmaceuticals (Basel) 2022;15:609. https:\/\/doi.org\/10.3390\/ph15050609 DOI: 10.3390\/ph15050609","DOI":"10.3390\/ph15050609"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"106. Romano A, Mortellaro A. The new frontiers of gene therapy and gene editing in inflammatory diseases. Hum Gene Ther 2024;35:219-231. https:\/\/doi.org\/10.1089\/hum.2023.210 DOI: 10.1089\/hum.2023.210","DOI":"10.1089\/hum.2023.210"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"107. Sisodiya SM. Precision medicine and therapies of the future. Epilepsia 2021;62(Suppl 2):S90-S105. https:\/\/doi.org\/10.1111\/epi.16539 DOI: 10.1111\/epi.16539","DOI":"10.1111\/epi.16539"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"108. He H, Cheng Q, Chen S, Li Q, Zhang J, Shan G, Zhang M. Triglyceride-glucose index and its additive interaction with ABCG2\/SLC2A9 polygenic risk score on hyperuricemia in middle age and older adults: findings from the DLCC and BHMC study. Ann Med 2024;56:2434186. https:\/\/doi.org\/10.1080\/07853890.2024.2434186 DOI: 10.1080\/07853890.2024.2434186","DOI":"10.1080\/07853890.2024.2434186"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"109. Roman YM. Moving the needle in gout management: the role of culture, diet, genetics, and personalized patient care practices. Nutrients 2022;14:3590. https:\/\/doi.org\/10.3390\/nu14173590 DOI: 10.3390\/nu14173590","DOI":"10.3390\/nu14173590"}],"container-title":["Physiological Research"],"original-title":[],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T15:20:36Z","timestamp":1764948036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2025\/74_693.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":109,"URL":"https:\/\/doi.org\/10.33549\/physiolres.935631","relation":{},"ISSN":["0862-8408","1802-9973"],"issn-type":[{"value":"0862-8408","type":"print"},{"value":"1802-9973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]}}}